Moreover, Ili-A showed efficacious activity against prostate cancer cells by abrogating EZH2/AR-mediated processes and demonstrated a synergistic anti-prostate cancer effect combined with enzalutamide in vivo, revealing a novel EZH2 inhibitor for the treatment of castration-resistant prostate cancer [22]. Here, EZH2 is linked to prostate carcinoma.